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Abstract
Objective We aimed to assess the safety of opioids in the management of osteoarthritis (OA) in a systematic review and 
meta-analysis of randomized, placebo-controlled trials.
Methods A comprehensive literature search was undertaken in the MEDLINE, Cochrane Central Register of Controlled 
Trials (Ovid CENTRAL), and Scopus electronic databases. Randomized, double-blind, placebo-controlled, parallel-group 
trials that assessed adverse events (AEs) with opioids in patients with OA were eligible for inclusion. Two authors appraised 
titles, abstracts and full-text papers for suitability and then assessed the studies for random sequence generation, allocation 
concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data and selec-
tive outcomes reporting. The primary outcomes of interest were gastrointestinal (GI) disorders, cardiac disorders, vascular 
disorders, nervous system disorders, skin and subcutaneous tissue disorders, renal and urinary disorders, respiratory, tho-
racic and mediastinal disorders, as well as overall severe and serious AEs and drug-related AEs. Secondary outcomes were 
withdrawals due to AEs (i.e. the number of participants who stopped the treatment due to an AE) and total number of AEs 
(i.e. the number of patients who experienced any AE at least once).
Results Database searches identified 2189 records, from which, after exclusions, 17 papers were included in the meta-
analysis. More disorders of the lower GI tract (constipation, fecaloma) were reported with both immediate-release (IR) and 
extended-release (ER) formulations of opioids versus placebo: IR opioids (relative risk [RR] 5.20, 95% confidence interval 
[CI] 3.42–7.89); ER opioids (RR 4.22, 95% CI 3.44–5.17). The risk of upper GI AEs increased fourfold with ER opioids 
compared with placebo (RR 4.03, 95% CI 0.87–18.62), and the risk of nausea, vomiting or loss of appetite increased four- 
to fivefold with both formulations: IR opioids (RR 3.39, 95% CI 2.22–5.18); ER opioids (RR 4.03, 95% CI 3.37–4.83). An 
increased risk of dermatologic AEs (rash and pruritis; IR opioids: RR 3.60, 95% CI 1.74–7.43; ER opioids: RR 7.87, 95% 
CI 5.20–11.89) and central nervous system disorders (dizziness, headache, fatigue, somnolence, insomnia; IR opioids: RR 
2.76, 95% CI 1.90–4.02; ER opioids: RR 2.76, 95% CI 2.19–3.47) was found with all opioid formulations versus placebo.
Conclusions Our results confirm that there are considerable safety and tolerability issues surrounding the use of opioids 
in OA, and support the recommendation of international and national guidelines to use opioids in OA after other analgesic 
options, and for short time periods.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4026 6-019-00666 -9) contains 
supplementary material, which is available to authorized users.
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Key Points 
Our analysis shows that oral opioids are associated 
with an increased risk of adverse events of the gastro-
intestinal, dermatologic, and central nervous systems 
when compared with placebo, regardless of whether the 
immediate-release or extended-release formulations are 
employed.
We recommend cautious use of opioids in the treatment 
of osteoarthritis in light of these findings.
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1 Introduction
Osteoarthritis (OA) is the most common form of joint dis-
ease and a leading cause of pain and physical disability 
in older people [1, 2]. OA is a progressive, degenerative 
disease of the synovial joints causing joint pain and func-
tional impairment with different degrees of disease sever-
ity that requires long-term management with various treat-
ment options over the course of the disease [3]. Opioids 
are potent analgesics that work by targeting mainly spinal 
and supraspinal opioid receptors. Cellular studies suggest 
that there are peripheral opioid receptors in inflamed osteo-
arthritic synovial tissue that may mediate analgesic effects 
[4]. Opioid prescription for OA is certainly common [5], 
but prescribing practices vary widely [6]. Opioids may be 
considered in OA if the pain is severe, or if other analgesics 
are contraindicated [7].
However, evidence regarding the safety and efficacy of 
opioids in OA is contradictory [8, 9], and thus some guide-
lines regard the use of opioids in OA as uncertain (the 
Osteoarthritis Research Society International [OARSI]) 
[10], while others limit their use to the last pharmacologic 
option for the severely symptomatic knee OA patient before 
surgery (the European Society for Clinical and Economic 
Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal 
Diseases [ESCEO]) [11, 12], or for patients with hip or knee 
OA who have had inadequate response to other therapies 
and are either unwilling to undergo or are not suitable can-
didates for surgery (the American College of Rheumatology 
[ACR]) [13].
A Cochrane review of oral or transdermal opioids in 22 
randomized controlled trials (RCTs) up to 2012 concluded 
that the small mean benefit of non-tramadol opioids is con-
trasted by a significant increase in the risk of adverse events 
(AEs) [7, 14]. The estimated effect size for pain was 0.28 
(standardized mean difference [SMD], 95% confidence inter-
val [CI] − 0.35 to − 0.20), which corresponds to a difference 
in pain score of 7 mm on a 100 mm visual analogue scale 
(VAS) between opioids and placebo; this was considered 
as being of questionable clinical relevance since the 95% 
CI did not include the minimal clinically important differ-
ence (MCID) of 0.37 SMD (9 mm on a VAS) [7]. AEs were 
more frequent in patients receiving opioids than controls; the 
relative risk (RR) of any AE was 1.49 (95% CI 2.93–4.82). 
Patients receiving opioids were nearly fourfold as likely to 
withdraw due to AEs (RR 3.76, 95% CI 3.06–5.38), and 
threefold as likely to experience a serious AE (SAE) [RR 
3.35, 95% CI 0.83–13.56) [14].
A meta-analysis of 19 RCTs and review of opioids 
found that in spite of analgesic effects, many OA patients 
stop chronic opioid use due to AEs. Analgesic effects were 
significantly better than placebo in opioid-treated patients 
(p = 0.01) [15, 16]; however, opioid treatment was associated 
with a significantly increased total dropout rate (odds ratio 
[OR] 1.3, 95% CI 1.2–1.4), and discontinuation of treatment 
was related to AEs (OR 4.0, 95% CI 3.4–4.6).
A recent meta-analysis of oral and transdermal opioids 
for pain in musculoskeletal conditions in older patients 
(aged > 60 years) found that opioid analgesics had only a 
limited effect on pain and disability. Opioids had a small 
effect on decreasing pain intensity (SMD − 0.27, 95% CI 
− 0.33 to − 0.20), while the odds of AEs with opioids were 
threefold higher (OR 2.94, 95% CI 2.33–3.72) and the odds 
of treatment discontinuation due to AEs was fourfold higher 
(OR 4.04, 95% CI 3.10–5.25) [17].
Extended-release (ER) or controlled-release (CR) formu-
lations may improve opioid tolerability in OA patients by 
preventing the high plasma peaks that are associated with the 
AEs observed with the immediate-release (IR) formulations 
[18]. A meta-analysis of four RCTs of patients with muscu-
loskeletal pain found that ER tapentadol (100–250 mg/day) 
is associated with a reduction in pain intensity in compari-
son with placebo and oxycodone. In addition, no increase in 
SAEs was reported when comparing tapentadol with placebo 
(RR 1.02, 95% CI 0.47–2.16) [19].
There is a paucity of meta-analysis data assessing the 
relative safety of opioids in OA, for both IR and ER formu-
lations. The objective of our study was to assess the safety 
of opioids in the management of OA in a systematic review 
and meta-analysis of randomized, placebo-controlled trials.
2  Methods
The protocol of this systematic review and meta-analysis 
was previously registered in the PROSPERO database (reg-
istration number CRD42017068249). The systematic review 
was performed in accordance with the recommendations in 
the Cochrane Handbook for Systematic Reviews of Inter-
ventions [20], and the findings are reported according to the 
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines [21]. The entire review pro-
cess (study selection and risk of bias assessment) was under-
taken using Covidence, the Cochrane platform for systematic 
reviews, and was performed by EC, NF, SS and LS.
2.1  Eligibility Criteria
Randomized, double-blind, placebo-controlled, parallel-
group trials that have assessed the AEs associated with oral 
opioids, i.e. IR (codeine, oxycodone, tramadol, tapentadol 
IR) and ER (CR codeine, CR oxycodone, CR tramadol, 
hydrocodone ER, morphine sulfate/sequestered naltrexone, 
OROS hydromorphone, tapentadol ER, morphine sulfate 
ER, oxymorphone ER), in comparison with placebo or other 
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oral analgesic comparator drugs (specifically non-steroidal 
anti-inflammatory drugs [NSAIDs], cyclooxygenase [COX-
2] inhibitors, paracetamol, nefopam hydrochloride, tricyclic 
antidepressants [amitriptyline, nortriptyline], gabapen-
tin, pregabalin and duloxetine) in patients with OA were 
identified.
Studies that allowed concomitant anti-OA treatments dur-
ing the trial (other than rescue medication as paracetamol or 
aspirin) were then excluded, as were animal trials.
2.2  Data Sources and Search Strategies
A comprehensive literature search was undertaken in the 
MEDLINE (via Ovid), Cochrane Central Register of Con-
trolled Trials (Ovid CENTRAL) and Scopus electronic data-
bases. We searched for randomized placebo-controlled tri-
als of opioids in OA, using a combination of study design-, 
treatment-, and disease-specific keywords and/or Medi-
cal Subject Heading (MeSH) terms. The databases were 
searched from inception to 30 June 2017.
While adverse effects were the outcomes of interest for 
this study, we decided to avoid the outcome-specific key-
words in the search strategies because of the possibility that 
a study on the efficacy of a drug may have not mentioned 
terms related to AEs in its title, abstract or in the keywords 
sections. The search was limited to English and French pub-
lications and to human subjects. Detailed search strategies 
for the MEDLINE/CENTRAL and Scopus databases are 
reported as electronic supplementary material (ESM) 1.
Two clinical trials registries, ClinicalTrials.gov (clinical-
trials.gov/) and the World Health Organization’s Interna-
tional Clinical Trials Registry Platform Search portal (apps.
who.int/trialsearch/) were also checked for trial results that 
would not have been published. Finally, recent meta-anal-
yses were also screened for any additional relevant studies.
2.3  Study Selection
Two members of the review team independently evaluated 
each title and abstract to exclude only obvious irrelevant 
studies, according to the predefined eligibility criteria. At 
this step, the criteria related to adverse effects was not con-
sidered for selection as studies focusing on the efficacy of 
a treatment may not report data about adverse effects in the 
abstract; this means that all trials mentioning only the effi-
cacy information were retrieved at this step. After this first 
step, the two investigators independently reviewed each of 
the full-text of the articles not excluded during the initial 
screening stage to determine whether the studies met all the 
selection criteria. At this stage, studies were excluded due 
to previously unidentified duplication, conference abstracts 
alone being available, the absence of a placebo arm against 
opioid medication in the trial, an indication other than OA, 
safety not being included as an outcome of the trial, a non-
opioid intervention, or incorrect study design. All differ-
ences of opinion regarding the selection of articles were 
resolved through discussion and consensus between the two 
investigators; any persistent disagreement was solved with 
the intervention of a third person (another member of the 
review team).
2.4  Data Extraction
The full-texts of the selected studies were screened by inde-
pendent reviewers for extraction of relevant data, using a 
standard data extraction form. Outcome results data were 
independently extracted by two investigators of the review 
team. For each study, the following data were extracted: 
characteristics of the manuscript, characteristics of the 
trial, objective and design of the study, characteristics of 
the patients, characteristics of the disease, characteristics 
of the treatments, AEs (outcomes) reported during the trial, 
and the main conclusion of the study. In the case of multi-
ple dosage arms for opioids being included in a trial, the 
maximum dose was used to categorize the study. If mul-
tiple follow-up times were included, the longest follow-up 
time was used to categorize the study. The raw data (number 
of events in each group) were extracted for each outcome. 
The number of patients who experienced any body system-
related AE at least once (e.g. nervous system, gastrointes-
tinal [GI] system), as well as AEs within each body system 
(e.g. headache, abdominal pain) were extracted. As much 
as possible, data from the intention-to-treat (ITT) analysis 
were considered.
2.5  Outcomes of Interest
The main System Organ Classes (SOCs) that are likely to 
be affected by the use of opioids in the treatment of OA 
were explored in this meta-analysis. The primary outcomes 
of interest were safety and tolerability outcomes, especially 
those associated with specific bodily systems, i.e. GI disor-
ders, cardiac disorders, vascular disorders, nervous system 
disorders, skin and subcutaneous tissue disorders, renal and 
urinary disorders, respiratory, thoracic and mediastinal dis-
orders, along with overall severe and serious AEs. Second-
ary outcomes were withdrawals due to AEs (i.e. the number 
of participants who stopped the treatment due to an AE), 
and the total number of AEs (i.e. the number of patients who 
experienced any AE at least once).
2.6  Assessment of Risk of Bias in the Included 
Studies
Two authors of the review team independently assessed the 
risk of bias in each study, using the Cochrane Collaboration’s 
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tool for risk of bias assessment [20]. The following charac-
teristics were evaluated:
• Random sequence generation: We assessed whether the 
allocation sequence was adequately generated.
• Allocation concealment: We assessed the method used 
to conceal the allocation sequence, evaluating whether 
the intervention allocation could have been foreseen in 
advance.
• Blinding of participants and personnel: We assessed 
the method used to blind study participants and person-
nel from knowledge of which intervention a participant 
received and whether the intended blinding was effective.
• Blinding of outcome assessment: We assessed the method 
used to blind outcome assessors from knowledge of 
which intervention a participant received and whether 
the intended blinding was effective.
• Incomplete outcome data: We assessed whether partici-
pants’ exclusions, attrition and incomplete outcome data 
were adequately addressed in the paper.
• Selective outcomes reporting: We checked whether there 
was evidence of selective reporting of AEs.
Each of these items was either categorized as either ‘low 
risk of bias’, ‘high risk of bias’, or ‘unclear risk of bias’. 
‘Low risk of bias’ or ‘high risk of bias’ was attributed for 
an item when there was sufficient information in the manu-
script to judge the risk of bias as ‘low’ or ‘high’, otherwise 
‘unclear risk of bias’ was attributed to the item. Disagree-
ments were solved by discussion between the two reviewers 
during a consensus meeting, and involved, when necessary, 
another member of the review team for final decision.
2.7  Data Analysis
Analyses were performed using STATA 14.2 software. The 
units of analysis were the number of participants experi-
encing a specific AE. We described harms associated with 
the treatment as risk ratio with 95% CI, and computed an 
overall effect size for each primary or secondary outcome 
(AE). Anticipating substantial variability among trial 
results (i.e. the interstudy variability), we assumed het-
erogeneity in the occurrence of the AEs; thus, we planned 
to use random-effects models for the meta-analyses. We 
estimated the overall effects and heterogeneity using the 
DerSimonian and Laird random-effects model [22]. As this 
method provides biased estimate of the between-study vari-
ance with sparse events [23, 24], we also performed the 
meta-analyses using the restricted maximum likelihood 
(REML) method [25].
We tested heterogeneity using the Cochran’s Q test. 
As we were performing a random-effect meta-analysis, 
we used the Tau-squared  (Tau2) estimate as the measure 
of the between-study variance. The I-squared (I2) sta-
tistic was used to quantify heterogeneity, measuring the 
percentage of total variation across studies due to het-
erogeneity [26]. In the case of substantial heterogeneity, 
we aimed to undertake subgroup analyses, stratifying the 
analyses according to participants’ age in the interven-
tion group, duration of the OA complaint, location of OA 
(knee, hand, hip), number of joints involved, drug dose, 
duration of the treatment, combination of the opioid anal-
gesic with other analgesics, analgesic potency of the opi-
oid (stronger vs. weaker); pharmacologic activity of the 
opioid analgesic (opioid receptors agonist only vs. opioid 
receptor agonists with other pharmacologic activity); and 
risk of bias in the study (e.g. studies with a low risk of 
bias versus all other studies). The quality of each evi-
dence was assessed using the Grading of Recommenda-
tions Assessment, Development and Evaluation (GRADE) 
approach [27], and a table summarising the findings was 
prepared using the GRADEpro online software [28].
3  Results
3.1  Study Selection
Database searches initially identified 2189 records. After 
exclusions, 61 articles were screened in full against the 
inclusion criteria. A flowchart (Fig. 1) with the number of 
studies at each step was established, including the reasons 
for excluding studies during the full-text reading process. 
Twenty-seven of these studies met the eligibility criteria, 
of which a further six were excluded as the trial lacked a 
placebo arm, and four were excluded as the reported out-
comes were not relevant to the meta-analysis. Finally, 17 
papers were included in the analysis of main study outcomes 
[29–45].
3.2  Study Characteristics
Table 1 presents the characteristics of the studies included 
through the systematic review process. The year of publi-
cation of the included studies ranged from 1998 to 2015, 
and the follow-up time ranged from 10 days to 16 weeks. 
Twelve studies included ER or CR formulations of opi-
oids, and five studies included IR opioids. The number 
of trials including an arm for each specific opioid (or two 
arms if two opioids were included) were as follows: trama-
dol, 8; oxycodone, 6; tapentadol, 2; hydromorphone, 2; 
and hydrocodone, 1 trial. Furthermore, the anatomical 
regions included per trial were as follows: knee, 15; hip, 
10; spine, 1; any location, 2; low back pain, 1; or awaiting 
joint replacement, two trials.
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3.3  Risk of Bias of Individual Studies
Figures 2 and 3 include a summary of the risk of bias 
assessed for each study included in the meta-analysis. The 
majority of our findings were associated with a ‘moderate’ 
to ‘high’ certainty of evidence, with the exception of total 
AEs (‘low’ certainty of evidence). Forest plots for analyses 
are reported in ESM 2.
3.4  Primary Outcomes
We reported only the results from the DerSimonian and 
Laird random-effects model because we found no difference 
in the effects computed by the two methods.
Too few studies reported data on severe or serious AEs 
(two studies of IR, two studies of ER) or drug-related 
AEs (one study of IR and no studies of ER) for opioids 
versus placebo, and thus the RR could not be calculated 
in this meta-analysis. The primary outcomes for SOC-
related AEs are reported separately for IR and ER opioid 
formulations.
3.4.1  Immediate‑Release Opioids
The RR of lower GI AEs (constipation or fecaloma) was 
significantly increased fivefold with IR opioids versus pla-
cebo (RR 5.20, 95% CI 3.42–7.89; I2 = 0%) [ESM 2]. The 
combined RR of nausea, vomiting or loss of appetite was 
significantly increased with IR opioids vs. placebo (RR 3.39, 
95% CI 2.22–5.18; I2 = 37.1%), and the risk of dry mouth or 
oral ulceration was also increased with IR opioids (RR 4.43, 
95% CI 0.92–21.24; I2 = 47.5%), although this did not reach 
statistical significance. The RR of upper GI complications 
with IR opioids could not be calculated as there insufficient 
data were reported in RCTs versus placebo.
The risk of AEs of the central nervous sys-
tem (CNS), including dizziness, headache and other 
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Fig. 1  Study selection process
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‘consciousness-related’ AEs (including insomnia, drowsi-
ness, sedation and fatigue) was significantly increased 
with IR opioids compared with placebo (RR 2.76, 95% CI 
1.90–4.02; I2 = 45.5%).
A significantly increased risk of dermatological AEs (rash 
and pruritus) was measured with IR opioids versus placebo 
(RR 3.60, 95% CI 1.74–7.43; I2 = 37.8%).
3.4.2  Extended‑Release Opioids
The RR of lower GI AEs (constipation) was significantly 
increased with ER opioids versus placebo (RR 4.22, 95% 
CI 3.44–5.17; I2 = 24.5%) [ESM 2], and the combined RR 
of nausea, vomiting or loss of appetite was significantly 
increased with ER opioids vs. placebo (RR 4.03, 95% 
CI 3.37–4.83; I2 = 33.4%). The risk of dry mouth or oral 
ulceration was also significantly increased with ER opioids 
vs. placebo (RR 3.00, 95% CI 1.85–4.86; I2 = 8.1%), and the 
RR of upper GI AEs (dyspepsia, gastritis, heartburn) was 
increased with ER opioids versus placebo (RR 4.03, 95% CI 
0.87–18.62; I2 = 0%), although this did not reach statistical 
significance.
The risk of AEs of the CNS was significantly increased 
with ER opioids compared with placebo (RR 2.76, 95% CI 
2.19–3.47; I2 = 72.9%). The RR of specific CNS AEs was 
as follows: headache (RR 0.98, 95% CI 0.83–1.16; I2 = 0%); 
dizziness (RR 3.63, 95% CI 2.98–4.41; I2 = 0%); and other 
(fatigue, somnolence, insomnia, weakness, nervousness) 
[RR 3.63, 95% CI 2.90–4.53; I2 = 14.9%].
A significantly increased risk of dermatological AEs (rash 
and pruritus) was measured with ER opioids versus placebo 
(RR 7.87, 95% CI 5.20–11.89; I2 = 0%).
Fig. 2  Risk of bias summary: review authors’ judgements about each risk of bias item for each included study
Fig. 3  Risk of bias graph: review authors’ judgements about each risk of bias item presented as percentages across all included studies
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3.5  Secondary Outcomes
For total AEs, a significant increased risk of AEs was found 
with ER opioids compared with placebo (RR 1.70, 95% CI 
1.37–2.12; I2 = 79.6%) [ESM 2]. Insufficient data were col-
lected on total AEs with IR opioid formulations versus pla-
cebo to allow comparison in this meta-analysis.
Heterogeneity in the reporting of withdrawal rates due 
to AEs between trials, with some articles reporting ‘dis-
continuations’, ‘withdrawn from study’ and an insufficient 
number providing a clear indication of withdrawals due to 
AEs meant that there were insufficient data to include the 
withdrawal rate in the meta-analysis.
3.6  GRADE Assessment of Findings
We assessed the certainty of evidence for each primary or 
secondary outcome for opioids compared with placebo, 
using the GRADE approach [27]. Our findings were largely 
associated with ‘moderate’ to ‘high’ certainty of evidence, 
with the exception of total AEs with ER opioids, for which 
there was low certainty of evidence. Additionally, for many 
outcomes, there were too few or no studies reporting on 
these outcomes for the GRADE analysis to be performed. 
Tables 2 and 3 summarize the findings for IR and ER opioids 
for all outcomes assessed in this meta-analysis.
4  Discussion
Overall, our meta-analysis found a significantly increased 
risk of lower GI, nausea/vomiting/loss of appetite, CNS and 
rash/pruritus in both IR and ER opioids compared with pla-
cebo. In addition, we found a significantly increased risk of 
dry mouth/oral ulceration, and total AEs with ER formula-
tions of opioids compared with placebo. This level of risk 
is comparable to the findings of a Cochrane meta-analysis 
of oral and transdermal (non-tramadol) opioids for OA of 
the knee or hip (da Costa et al. [7] and a recent systematic 
review and meta-analysis of older people [aged ≥ 60 years] 
with musculoskeletal pain by Megale et al. [17]). These 
results may reflect physiological changes in pain process-
ing, pharmacokinetics, and pharmacodynamics in the aging 
population.
Insufficient data were reported on total AEs and upper 
GI complications with IR formulations of opioids versus 
placebo to allow inclusion of a comparison in our meta-
analysis. Controlled-, sustained-, and extended-release for-
mulations are designed to avoid the peaks (and troughs) of 
plasma drug concentrations that are associated with the 
tolerability issues of IR formulations. A fivefold increased 
risk of lower GI AEs (constipation), threefold combined 
increase in nausea, vomiting and loss of appetite, and 
threefold increase in dermatological AEs was measured 
with IR opioids compared with placebo.
Our analysis demonstrates that ER opioid formulations 
are nonetheless associated with a higher rate of AEs com-
pared with placebo: fourfold increase in lower GI AEs, 
fourfold increase in nausea, vomiting and loss of appetite, 
threefold increase in dry mouth or ulceration, and seven-
fold increase in dermatological AEs (rash or pruritis). A 
significantly increased risk of CNS AEs occurred with 
both IR and ER opioids (RR 2.76 for each group), largely 
relating to sedation, drowsiness, fatigue, dizziness and 
headache.
Tramadol is a centrally-acting weak opioid analgesic 
with a dual mode of action as an agonist of the μ-opioid 
receptor and as a noradrenaline reuptake inhibitor, which 
rarely causes the AEs of respiratory depression and physi-
cal dependence commonly associated with conventional 
opioid drugs [46]. A review of tramadol found a small but 
statistically significant benefit for tramadol over placebo in 
OA (number needed to treat to benefit [NNTB] = 6, 95% 
CI 4–9); however, the high level of reversible and non-life-
threatening AEs reported (number needed to treat to harm 
[NNTH] = 8, 95% CI 7–12) often caused the participant to 
withdraw (12.5% of patients taking tramadol), which could 
limit its usefulness in clinical practice [15]. Our analysis 
included tramadol in both IR and CR formulations. As an 
IR formulation, tramadol was associated with GI adverse 
effects (constipation, nausea, vomiting), CNS AEs (dizzi-
ness, headache, fatigue, insomnia, somnolence) and der-
matological AEs (itching and pruritus). The CR formula-
tion of tramadol (200–400 mg) was a major contributor 
to the significantly higher rate of AEs observed with all 
ER formulations (hydromorphone, oxycodone) included 
in our study compared with placebo (RR 1.70, 95% CI 
1.37–2.12). There is some evidence to suggest that the rate 
of AEs with tramadol can be minimized with slow upward 
titration of an ER formulation, to improve tolerability and 
thus avoid premature treatment discontinuations [47].
Like tramadol, tapentadol has a dual mechanism of 
action, but unlike tramadol, it has only weak effects on the 
reuptake of serotonin and is a significantly more potent 
opioid with no known active metabolites [48, 49]. Tapen-
tadol ER (75 mg 4–6 hourly and 100–250 mg/day) in two 
studies included in our meta-analysis was also associated 
with a higher risk of AEs, including GI disorders (constipa-
tion, nausea, vomiting, dry mouth, oral ulceration), CNS 
disorders (dizziness, somnolence, fatigue) and dermato-
logical AEs (rash and pruritus) compared with placebo. In 
an analysis of four studies of tapentadol ER versus placebo 
or oxycodone in patients with OA or back pain, tapent-
adol ER was associated with a 2.7-fold increase in risk of 
discontinuation due to AEs compared with placebo, but 
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with a 50% reduction in risk of discontinuation due to AEs 
compared with oxycodone [19].
4.1  Limitations
Around half of the studies identified that met the inclusion 
criteria did not provide AE data suitable for inclusion in the 
meta-analysis. Many studies lacked detail on AE reporting 
and there was variation between studies regarding nomen-
clature and grouping of AEs e.g. ‘common adverse events’, 
or ‘those experienced in > 5%’. These different names and 
groupings of AEs may lead to lack of resolution and possible 
double counting. In combining different drugs and doses into 
one meta-analysis, we have chosen the highest dose when 
multiple doses were presented in a trial, e.g. ‘tramadol ER 
100/200/300/400 mg’, which could lead to an exaggeration 
of AEs. Sensitivity analysis of the two approaches (highest 
dose, versus multiple dose) revealed only marginal differ-
ences in the magnitude of the outcome. Included studies 
were of short duration, i.e. only 2–18 weeks. Our analy-
sis was limited to studies in OA patients, thus safety issues 
could be missed in relevant subgroups, e.g. other musculo-
skeletal pain, back pain. Our meta-analysis did not examine 
IR formulations against ER formulations, however this could 
be a potential avenue for future research.
5  Conclusions
In our meta-analysis, oral opioids were associated with an 
increased risk of GI, CNS and dermatological AEs com-
pared with placebo, for both the IR and ER formulations. 
The frequent occurrence of adverse effects limits the use of 
opioids due to poor tolerability and high rates of treatment 
withdrawal. To maximize the risk: benefit ratio of opioids, 
the ESCEO recommends that opioids should only be used 
as a step 3 treatment for severely symptomatic OA patients, 
preferably as short-term treatment with a weak opioid [11]. 
Our results confirm that there are considerable safety and 
tolerability issues surrounding the use of opioids in OA, and 
support the recommendation of international and national 
guidelines to reserve the use of opioids in OA as the last 
resort pharmacologic therapy before surgery [10–13].
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